CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)

I Puértolas Tena; MA Alcácera López; M Merchante Andreu; E Fernández Alonso; M Gimeno Gracia; S Gamarra Calvo; MP Pardo Jario

doi:10.1136/ejhpharm-2016-000875.169

Citation Tools

Clinical pharmacy

CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Tena IP, López MA, Andreu MM, et al

CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)

European Journal of Hospital Pharmacy 2016;23:A75.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password